Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats

  • Gwak, Eun Hye (College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University) ;
  • Yoo, Hee Young (College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University) ;
  • Kim, So Hee (College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University)
  • Received : 2020.01.16
  • Accepted : 2020.02.21
  • Published : 2020.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Tofacitinib, a Janus kinase inhibitor, was developed for the treatment of rheumatoid arthritis. Recently, it has been associated with an increased change in arthritis development in patients with diabetes. Herein, we evaluated the pharmacokinetics of tofacitinib after intravenous (10 mg/kg) and oral (20 mg/kg) administration to rats with streptozotocin-induced diabetes mellitus and control rats. Following intravenous administration of tofacitinib to rats with streptozotocin-induced diabetes mellitus, area under the plasma concentration-time curve from time zero to infinity of tofacitinib was significantly smaller (33.6%) than that of control rats. This might be due to the faster hepatic intrinsic clearance (112%) caused by an increase in the hepatic cytochrome P450 (CYP) 3A1(23) and the faster hepatic blood flow rate in rats with streptozotocin-induced diabetes mellitus than in control rats. Following oral administration, area under the plasma concentration-time curve from time zero to infinity of tofacitinib was also significantly smaller (55.5%) in rats with streptozotocin-induced diabetes mellitus than that in control rats. This might be due to decreased absorption caused by the higher expression of P-glycoprotein and the faster intestinal metabolism caused by the higher expression of intestinal CYP3A1(23), which resulted in the decreased bioavailability of tofacitinib (33.0%) in rats with streptozotocin-induced diabetes mellitus. In summary, our findings indicate that diabetes mellitus affects the absorption and metabolism of tofacitinib, causing faster metabolism and decreased intestinal absorption in rats with streptozotocin-induced diabetes mellitus.

Keywords

References

  1. Antonelli, E., Villanacci, V. and Bassotti, G. (2018) Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J. Gastroenterol. 24, 5322-5330. https://doi.org/10.3748/wjg.v24.i47.5322
  2. Bachelez, H., van de Kerkhof, P. C., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J. H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., Gupta, P., Tan, H., Tawadrous, M., Valdez, H. and Wolk, R.; OPT Compare Investigators (2015) Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386, 552-561. https://doi.org/10.1016/S0140-6736(14)62113-9
  3. Bae, S. H., Park, J. H., Choi, H. G., Kim, H. and Kim, S. H. (2018) Imidazole antifungal drugs inhibit the cell proliferation and invasion of human breast cancer cells. Biomol. Ther. (Seoul) 26, 494-502. https://doi.org/10.4062/biomolther.2018.042
  4. Carnovale, C. E., Marinelli, R. A. and Rodriguez Garay, E. A. (1986) Bile flow decrease and altered bile composition in streptozotocintreated rats. Biochem. Pharmacol. 35, 2625-2628. https://doi.org/10.1016/0006-2952(86)90063-8
  5. Chiou, W. L. (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6, 539-546. https://doi.org/10.1007/BF01062108
  6. Choi, Y. H., Lee, D. C. and Lee, M. G. (2008) Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J. Pharm. Sci. 97, 5363-5375. https://doi.org/10.1002/jps.21349
  7. Claxton, L., Taylor, M., Soonasra, A., Bourret, J. A. and Gerber, R. A. (2018) An economic evaluation of tofacitinib treatment in rheumatoid arthritis after methotrexate or after 1 or 2 TNF inhibitors from a U.S. payer perspective. J. Manag. Care Spec. Pharm. 24, 1010-1017. https://doi.org/10.18553/jmcp.2018.17220
  8. Coombs, J. H., Bloom, B. J. and Breedveld, F. C. (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from randomized, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 69, 413-416. https://doi.org/10.1136/ard.2009.108159
  9. Dowty, M. E., Lin, J., Ryder, T. F., Wang, W., Walker, G. S., Vaz, A., Chan, G. L., Krishnaswami, S. and Prakash, C. (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab. Dispos. 42, 759-773. https://doi.org/10.1124/dmd.113.054940
  10. Duggleby, R. G. (1995) Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol. 249, 61-90. https://doi.org/10.1016/0076-6879(95)49031-0
  11. Fukuda, T., Naganuma, M. and Kanai, T. (2019) Current new challenges in the management of ulcerative colitis. Intest. Res. 17, 36-44. https://doi.org/10.5217/ir.2018.00126
  12. Gibaldi, M. and Perrier, D. (1982) Pharmacokinetics, 2nd ed. Marcel-Dekker, New York.
  13. Gupta, P., Alvey, C. and Wang, R. (2012) Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. Br. J. Clin. Pharmacol. 74, 109-115. https://doi.org/10.1111/j.1365-2125.2012.04168.x
  14. Hussa, D. A. (2014) 2013 new drug update: what do new approvals hold for the elderly? Consult. Pharm. 29, 224-238. https://doi.org/10.4140/TCP.n.2014.224
  15. Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C., Marinkovich, M. P., Christiano, A. M., Oro, A. E. and King, B. A. (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1, e89776.
  16. Kim, S. H., Choi, Y. M. and Lee, M. G. (1993) Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm. 21, 1-17. https://doi.org/10.1007/BF01061772
  17. Kim, S. H., Lee. J. S. and Lee, M. G. (1999) Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative. Biopharm. Drug Dispos. 20, 355-360. https://doi.org/10.1002/(SICI)1099-081X(199910)20:7<355::AID-BDD197>3.0.CO;2-X
  18. Kim, Y. C., Lee, A. K., Lee, J. H., Lee, I., Lee, D. C., Kim, S. H., Kim, S. G. and Lee, M. G. (2005) Pharmacokinetics of theophylline in diabetes mellitus rat: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur. J. Pharm. Sci. 26, 114-123. https://doi.org/10.1016/j.ejps.2005.05.004
  19. LaBranchem, T, P., Jesson, M. I., Radi, Z. A., Storer, C. E., Guzova, J. A., Bonar, S. L., Thompson, J. M., Happa, F. A., Stewart, Z. S., Zhan, Y., Bollinger, C. S., Bansal, P. N., Wellen, J. W., Wilkie, D. P., Bailey, S. A., Symanowicz, P. T., Hegen, M., Head, R. D., Kishore, N., Mbalaviele, G. and Meyer, D. M. (2012) JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 64, 3531-3542. https://doi.org/10.1002/art.34649
  20. Lawendy, N., Krishnaswami, S., Wang, R., Gruben, D., Cannon, C., Swan, S. and Chan, G. (2009) Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J. Clin. Pharmacol. 49, 423-429. https://doi.org/10.1177/0091270008330982
  21. Lee, D. Y., Chung, H. J., Choi, Y. H., Lee, U., Kim, S. H., Lee, I. and Lee, M. G. (2009) Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. Eur. J. Pharm. Sci. 38, 465-471. https://doi.org/10.1016/j.ejps.2009.09.008
  22. Lee, J. S. and Kim, S. H. (2019) Dose-dependent pharmacokinetics of tofacitinib in rats: influence of hepatic and intestinal first-pass metabolism. Pharmaceutics 11, e318.
  23. Lee, D. Y., Lee, M. G., Shin, H. S. and Lee, I. (2007) Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1. J. Pharm. Pharm. Sci. 10, 420-433. https://doi.org/10.18433/J3WC7G
  24. Lee, J. H., Yang, S. H., Oh, J. M. and Lee, M. G. (2010) Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J. Pharm. Pharmacol. 62, 1-23. https://doi.org/10.1211/jpp.62.01.0001
  25. Levy, L. L., Urban, J. and King, B. A. (2015) Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J. Am. Acad. Dermatol. 73, 395-399. https://doi.org/10.1016/j.jaad.2015.06.045
  26. Ma, G., Xie, R., Strober, B., Langley, R., Ito, K., Krishnaswami, S., Wolk, R., Valdez, H., Rottinghaus, S., Tallman, A. and Gupta, R. (2018) Pharmacokinetic characteristics of tofacitinib in adult patients with moderate to severe chronic plaque psoriasis. Clin. Pharmacol. Drug Dev. 7, 584-596.
  27. Mitruka, B. M. and Rawnsley, H. M. (1981) Clinical Biomedical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, 2nd ed. Masson Publishing, USA Inc., New York.
  28. Molsted, S., Bjorkman, A. S. D., Andersen, M. B. and Ekholm, O. (2018) Diabets is associated with elevated risks of osteoarthritis, osteoporosis and rheumatoid arthritis. 54th Annual Meeting of the European Association for the Study of Diabetes (EASD). Abstract 1112, Oct. 1-5, 2018. Berlin, Germany.
  29. Nadai, M., Yoshizumi, H., Kuzuya, T., Hasgawa, T., Johno, I. and Kitazawa, S. K. (1990) Effects of diabetes on disposition and renal handling of cefazolin in rats. J. Pharmacol. Exp. Ther. 18, 565-570.
  30. Papp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., Gupta, P., Proulx, J., Lan, S. and Wolk, R.; OPT Pivotal 1 and OPT Pivotal 2 investigators (2015) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br. J. Dermatol. 173, 949-961. https://doi.org/10.1111/bjd.14018
  31. Park, J. M., Moon, C. H. and Lee, M. G. (1996) Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. Res. Commun. Mol. Pathol. Pharmacol. 93, 343-352.
  32. Pickup, J. C. and Williams, G. (1991) Textbook of Diabetes. Blackwell Scientific Publications, Oxford.
  33. Riese, R. J., Krishnaswami, S. and Kremer, J. (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract. Res. Clin. Rheumatol. 24, 5513-5526.
  34. Sato, H., Terasaki, T., Okumura, K. and Tsuji, A. (1991) Effect of receptor-up-regulation on insulin pharmacokinetics in streptozotocintreated diabetic rats. Pharm. Res. 8, 563-569. https://doi.org/10.1023/A:1015888203572
  35. Shin, W. G., Lee, M. G., Lee, M. H. and Kim, N. D. (1991) Factors influencing the protein binding of vancomycin. Biopharm. Drug Dispos. 12, 637-646. https://doi.org/10.1002/bdd.2510120902
  36. Svein, O. and Theodor, W. G. (1982) Comparison of equilibrium time in dialysis experiments using spiked plasma or spiked buffer. J. Pharm. Sci. 71, 127-128. https://doi.org/10.1002/jps.2600710136
  37. Tahir, H. (2018) Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology (Oxford) 57, vi23-vi28.
  38. Vincenti, F., Tedesco Silva, H., Busque, S., O'Connell, P., Friedewald, J., Cibrik, D., Budde, K., Yoshida, A., Cohney, S., Weimar, W., Kim, Y. S., Lawendy, N., Lan, S. P., Kudlacz, E., Krishnaswami, S. and Chan, G. (2012) Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am. J. Transplant. 12, 2446-2456. https://doi.org/10.1111/j.1600-6143.2012.04127.x
  39. Watkins, J. B., III and Sandeors, R. A. (1995) Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol. Rev. 47, 1-23.
  40. Watkins, J. B. III and Sherman, S. E. (1992) Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J. Pharmacol. Exp. Ther. 260, 1337-1343.

Cited by

  1. Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment vol.215, 2020, https://doi.org/10.1016/j.pharmthera.2020.107627
  2. Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats vol.13, pp.5, 2020, https://doi.org/10.3390/pharmaceutics13050740
  3. Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments vol.44, pp.3, 2020, https://doi.org/10.1080/25785826.2020.1825276